Concepts (311)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Personhood | 2 | 2019 | 14 | 1.220 |
Why?
|
| Dementia | 5 | 2025 | 460 | 1.000 |
Why?
|
| Australia | 20 | 2025 | 185 | 0.860 |
Why?
|
| Reproductive Techniques, Assisted | 4 | 2016 | 76 | 0.840 |
Why?
|
| Art | 2 | 2019 | 5 | 0.760 |
Why?
|
| Alzheimer Disease | 2 | 2019 | 857 | 0.710 |
Why?
|
| Embryo Transfer | 8 | 2022 | 56 | 0.690 |
Why?
|
| Fertilization in Vitro | 8 | 2019 | 161 | 0.680 |
Why?
|
| Ploidies | 2 | 2019 | 36 | 0.650 |
Why?
|
| Spindle Apparatus | 2 | 2019 | 50 | 0.640 |
Why?
|
| Infertility, Male | 3 | 2023 | 296 | 0.570 |
Why?
|
| Oocytes | 2 | 2019 | 290 | 0.550 |
Why?
|
| Palliative Care | 6 | 2025 | 456 | 0.550 |
Why?
|
| Research Design | 3 | 2024 | 742 | 0.550 |
Why?
|
| Infertility, Female | 3 | 2019 | 149 | 0.530 |
Why?
|
| Caregivers | 4 | 2025 | 588 | 0.520 |
Why?
|
| Family | 2 | 2022 | 595 | 0.510 |
Why?
|
| Ovulation Induction | 3 | 2018 | 42 | 0.500 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2015 | 77 | 0.480 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2015 | 193 | 0.470 |
Why?
|
| Fertility Agents, Female | 1 | 2015 | 9 | 0.470 |
Why?
|
| Hormone Antagonists | 1 | 2015 | 49 | 0.470 |
Why?
|
| Blastocyst | 4 | 2022 | 78 | 0.460 |
Why?
|
| Multiple Birth Offspring | 1 | 2014 | 6 | 0.450 |
Why?
|
| Embryonic Development | 1 | 2016 | 215 | 0.430 |
Why?
|
| Shock, Hemorrhagic | 3 | 2020 | 55 | 0.420 |
Why?
|
| Progesterone | 1 | 2015 | 451 | 0.390 |
Why?
|
| Acupuncture Therapy | 3 | 2019 | 13 | 0.390 |
Why?
|
| Biomedical Research | 2 | 2025 | 553 | 0.390 |
Why?
|
| Pregnancy Rate | 4 | 2022 | 40 | 0.380 |
Why?
|
| Ethics Committees, Research | 1 | 2011 | 32 | 0.360 |
Why?
|
| Reproductive Medicine | 1 | 2011 | 20 | 0.360 |
Why?
|
| Ring Chromosomes | 1 | 2011 | 13 | 0.350 |
Why?
|
| Research Support as Topic | 1 | 2011 | 62 | 0.350 |
Why?
|
| Luteal Phase | 1 | 2010 | 9 | 0.340 |
Why?
|
| Ovarian Diseases | 1 | 2010 | 25 | 0.340 |
Why?
|
| Azoospermia | 1 | 2011 | 48 | 0.340 |
Why?
|
| Multifactorial Inheritance | 2 | 2021 | 167 | 0.330 |
Why?
|
| Infant, Low Birth Weight | 2 | 2014 | 174 | 0.320 |
Why?
|
| Blood Component Transfusion | 2 | 2020 | 58 | 0.320 |
Why?
|
| Version, Fetal | 1 | 2009 | 6 | 0.320 |
Why?
|
| Breech Presentation | 1 | 2009 | 20 | 0.320 |
Why?
|
| Tranexamic Acid | 2 | 2020 | 33 | 0.310 |
Why?
|
| Pregnancy | 17 | 2023 | 7554 | 0.310 |
Why?
|
| Live Birth | 3 | 2018 | 72 | 0.300 |
Why?
|
| Humans | 54 | 2025 | 132013 | 0.300 |
Why?
|
| Terminal Care | 2 | 2020 | 120 | 0.300 |
Why?
|
| Resuscitation | 2 | 2020 | 270 | 0.270 |
Why?
|
| Blood Coagulation Disorders | 2 | 2020 | 109 | 0.250 |
Why?
|
| Female | 35 | 2025 | 70643 | 0.250 |
Why?
|
| Cesarean Section | 1 | 2009 | 418 | 0.250 |
Why?
|
| Patient Selection | 2 | 2025 | 732 | 0.240 |
Why?
|
| Hospitalization | 1 | 2014 | 1897 | 0.240 |
Why?
|
| Adult | 23 | 2024 | 31563 | 0.230 |
Why?
|
| Stakeholder Participation | 1 | 2025 | 32 | 0.230 |
Why?
|
| Cryopreservation | 3 | 2015 | 70 | 0.230 |
Why?
|
| Urodynamics | 1 | 2024 | 40 | 0.220 |
Why?
|
| Benzodiazepines | 1 | 2025 | 108 | 0.220 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2024 | 34 | 0.220 |
Why?
|
| Fluorobenzenes | 2 | 2014 | 39 | 0.210 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 78 | 0.210 |
Why?
|
| Consensus | 2 | 2025 | 649 | 0.210 |
Why?
|
| Fibrinolysis | 2 | 2020 | 44 | 0.210 |
Why?
|
| Postmenopause | 1 | 2024 | 153 | 0.210 |
Why?
|
| Biological Specimen Banks | 1 | 2024 | 56 | 0.210 |
Why?
|
| Aging | 3 | 2023 | 1249 | 0.200 |
Why?
|
| Pyrroles | 2 | 2014 | 182 | 0.190 |
Why?
|
| Plasma | 2 | 2020 | 103 | 0.190 |
Why?
|
| Patient Participation | 1 | 2025 | 240 | 0.190 |
Why?
|
| Thrombelastography | 2 | 2020 | 63 | 0.190 |
Why?
|
| Health Personnel | 2 | 2025 | 543 | 0.190 |
Why?
|
| Light | 2 | 2019 | 183 | 0.180 |
Why?
|
| Sulfonamides | 2 | 2014 | 282 | 0.180 |
Why?
|
| Antifibrinolytic Agents | 2 | 2020 | 49 | 0.180 |
Why?
|
| Sperm Injections, Intracytoplasmic | 3 | 2019 | 46 | 0.180 |
Why?
|
| Urogenital Abnormalities | 1 | 2023 | 164 | 0.180 |
Why?
|
| Metadata | 1 | 2021 | 6 | 0.180 |
Why?
|
| Blood Proteins | 1 | 2021 | 136 | 0.170 |
Why?
|
| Sports Medicine | 1 | 2021 | 30 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2014 | 418 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 316 | 0.170 |
Why?
|
| Premature Birth | 1 | 2005 | 418 | 0.170 |
Why?
|
| Musculoskeletal Diseases | 1 | 2021 | 56 | 0.170 |
Why?
|
| Shock, Traumatic | 1 | 2020 | 7 | 0.170 |
Why?
|
| Athletic Injuries | 1 | 2021 | 66 | 0.160 |
Why?
|
| First Aid | 1 | 2020 | 6 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 139 | 0.160 |
Why?
|
| Hypocalcemia | 1 | 2020 | 38 | 0.160 |
Why?
|
| Weather | 1 | 2019 | 14 | 0.160 |
Why?
|
| Wounds and Injuries | 2 | 2020 | 393 | 0.160 |
Why?
|
| Proteome | 1 | 2021 | 279 | 0.160 |
Why?
|
| Photosensitizing Agents | 1 | 2019 | 35 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2023 | 5166 | 0.150 |
Why?
|
| Photochemotherapy | 1 | 2019 | 41 | 0.150 |
Why?
|
| Pregnancy Outcome | 5 | 2023 | 635 | 0.150 |
Why?
|
| Social Networking | 1 | 2019 | 17 | 0.150 |
Why?
|
| Friends | 1 | 2019 | 18 | 0.150 |
Why?
|
| Wounds, Penetrating | 1 | 2020 | 142 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 342 | 0.150 |
Why?
|
| Culture | 1 | 2019 | 72 | 0.150 |
Why?
|
| Complement C5a | 1 | 2019 | 22 | 0.150 |
Why?
|
| Parasites | 1 | 2019 | 36 | 0.140 |
Why?
|
| Databases, Genetic | 1 | 2021 | 501 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 899 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2022 | 249 | 0.140 |
Why?
|
| Violence | 1 | 2019 | 128 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2024 | 6568 | 0.140 |
Why?
|
| Referral and Consultation | 2 | 2019 | 569 | 0.140 |
Why?
|
| Visual Perception | 1 | 2019 | 133 | 0.140 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2020 | 221 | 0.140 |
Why?
|
| Personal Autonomy | 1 | 2019 | 205 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 241 | 0.130 |
Why?
|
| Male | 19 | 2025 | 64914 | 0.130 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 233 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2019 | 391 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2021 | 510 | 0.130 |
Why?
|
| Coronary Artery Disease | 2 | 2014 | 891 | 0.130 |
Why?
|
| Hospitals | 2 | 2022 | 438 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2020 | 503 | 0.130 |
Why?
|
| Maternal-Child Nursing | 1 | 2016 | 2 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 305 | 0.120 |
Why?
|
| Aged | 10 | 2025 | 21406 | 0.120 |
Why?
|
| Software | 1 | 2021 | 731 | 0.120 |
Why?
|
| Immunization Programs | 1 | 2016 | 65 | 0.120 |
Why?
|
| Consumer Behavior | 1 | 2016 | 33 | 0.120 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2015 | 12 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 416 | 0.120 |
Why?
|
| Preimplantation Diagnosis | 1 | 2016 | 27 | 0.120 |
Why?
|
| Perinatal Care | 1 | 2016 | 68 | 0.120 |
Why?
|
| Fertility Preservation | 1 | 2016 | 58 | 0.120 |
Why?
|
| Western Australia | 1 | 2014 | 5 | 0.110 |
Why?
|
| Calcium | 1 | 2020 | 1079 | 0.110 |
Why?
|
| Middle Aged | 13 | 2024 | 28968 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 632 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 669 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2016 | 232 | 0.110 |
Why?
|
| Neoplasms | 2 | 2022 | 2956 | 0.110 |
Why?
|
| Arachidonic Acid | 1 | 2014 | 67 | 0.110 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2014 | 49 | 0.110 |
Why?
|
| Abortion, Spontaneous | 2 | 2012 | 84 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2016 | 289 | 0.100 |
Why?
|
| Stillbirth | 1 | 2014 | 103 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2021 | 1074 | 0.100 |
Why?
|
| Embryo, Mammalian | 1 | 2015 | 440 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2016 | 323 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2019 | 793 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 133 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 902 | 0.100 |
Why?
|
| Anxiety | 1 | 2019 | 991 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17374 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2014 | 239 | 0.090 |
Why?
|
| New Zealand | 3 | 2019 | 60 | 0.090 |
Why?
|
| Vaccines | 1 | 2016 | 381 | 0.090 |
Why?
|
| Pediatrics | 1 | 2021 | 1211 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2023 | 8542 | 0.090 |
Why?
|
| Oligospermia | 1 | 2011 | 62 | 0.090 |
Why?
|
| Acute Coronary Syndrome | 1 | 2014 | 244 | 0.090 |
Why?
|
| Infertility | 1 | 2012 | 81 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2011 | 102 | 0.090 |
Why?
|
| United Kingdom | 1 | 2011 | 235 | 0.090 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2015 | 75 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 464 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2025 | 664 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2021 | 1256 | 0.080 |
Why?
|
| Quality of Life | 4 | 2023 | 2157 | 0.080 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2009 | 1 | 0.080 |
Why?
|
| Fibrinolysin | 2 | 2020 | 12 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 606 | 0.080 |
Why?
|
| Metformin | 2 | 2015 | 166 | 0.080 |
Why?
|
| Midwifery | 1 | 2009 | 41 | 0.080 |
Why?
|
| Genetic Counseling | 1 | 2011 | 245 | 0.080 |
Why?
|
| Home Childbirth | 1 | 2009 | 39 | 0.080 |
Why?
|
| Injury Severity Score | 2 | 2020 | 230 | 0.080 |
Why?
|
| Health Policy | 1 | 2011 | 233 | 0.080 |
Why?
|
| Triplets | 1 | 2008 | 11 | 0.080 |
Why?
|
| Young Adult | 6 | 2021 | 9952 | 0.070 |
Why?
|
| Obstetric Labor Complications | 1 | 2009 | 99 | 0.070 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2020 | 120 | 0.070 |
Why?
|
| Length of Stay | 1 | 2014 | 1380 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2014 | 716 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 1246 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2020 | 12987 | 0.070 |
Why?
|
| Glasgow Coma Scale | 2 | 2020 | 200 | 0.060 |
Why?
|
| Gonadotropins | 1 | 2006 | 32 | 0.060 |
Why?
|
| Incidence | 2 | 2014 | 3375 | 0.060 |
Why?
|
| Hemorrhage | 2 | 2020 | 518 | 0.060 |
Why?
|
| Anthropology, Cultural | 1 | 2025 | 6 | 0.060 |
Why?
|
| Critical Care | 2 | 2020 | 686 | 0.060 |
Why?
|
| Premenopause | 1 | 2024 | 40 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2311 | 0.050 |
Why?
|
| Rosuvastatin Calcium | 2 | 2014 | 43 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2023 | 14736 | 0.050 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2024 | 30 | 0.050 |
Why?
|
| Menopause | 1 | 2024 | 90 | 0.050 |
Why?
|
| Fertility | 2 | 2016 | 258 | 0.050 |
Why?
|
| Time Factors | 3 | 2020 | 6441 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1671 | 0.050 |
Why?
|
| Semen | 1 | 2023 | 81 | 0.050 |
Why?
|
| Health Services | 1 | 2023 | 70 | 0.050 |
Why?
|
| Maternal Age | 2 | 2016 | 139 | 0.050 |
Why?
|
| Informed Consent | 1 | 2025 | 346 | 0.050 |
Why?
|
| England | 1 | 2021 | 63 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 45 | 0.050 |
Why?
|
| Biomarkers | 2 | 2021 | 3402 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 309 | 0.040 |
Why?
|
| Infection Control | 1 | 2022 | 157 | 0.040 |
Why?
|
| Risk Factors | 4 | 2020 | 10931 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 201 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3352 | 0.040 |
Why?
|
| Benchmarking | 1 | 2021 | 138 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 293 | 0.040 |
Why?
|
| Physical Examination | 1 | 2021 | 165 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2020 | 67 | 0.040 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.040 |
Why?
|
| Sunlight | 1 | 2019 | 26 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 68 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 105 | 0.040 |
Why?
|
| Sperm Count | 1 | 2019 | 91 | 0.040 |
Why?
|
| Plasminogen | 1 | 2019 | 8 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 726 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 5409 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2019 | 38 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 263 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 600 | 0.040 |
Why?
|
| Time | 1 | 2019 | 98 | 0.040 |
Why?
|
| Thrombin | 1 | 2019 | 60 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2020 | 291 | 0.040 |
Why?
|
| Animals | 4 | 2019 | 34804 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 216 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2019 | 130 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 562 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 243 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2655 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 246 | 0.030 |
Why?
|
| Research | 1 | 2019 | 265 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 51 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 523 | 0.030 |
Why?
|
| Single Embryo Transfer | 1 | 2015 | 2 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1572 | 0.030 |
Why?
|
| Patient Care Bundles | 1 | 2016 | 26 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 875 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 858 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 767 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 192 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3993 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 20544 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 795 | 0.030 |
Why?
|
| Apolipoproteins A | 1 | 2014 | 54 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 41 | 0.030 |
Why?
|
| Genome, Human | 1 | 2021 | 1331 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2014 | 140 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2014 | 61 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 3008 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2014 | 69 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 7105 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1829 | 0.030 |
Why?
|
| Physicians | 1 | 2020 | 640 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 436 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1300 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2911 | 0.020 |
Why?
|
| Reference Values | 1 | 2014 | 703 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 398 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 1992 | 89 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1441 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 662 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 482 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2014 | 320 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1222 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2012 | 207 | 0.020 |
Why?
|
| Vaccination | 1 | 2016 | 1018 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1127 | 0.020 |
Why?
|
| Rats | 2 | 2014 | 3606 | 0.020 |
Why?
|
| Cleavage Stage, Ovum | 1 | 2010 | 4 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2014 | 547 | 0.020 |
Why?
|
| Embryo Culture Techniques | 1 | 2010 | 22 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1500 | 0.020 |
Why?
|
| New South Wales | 1 | 2009 | 12 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1439 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 984 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 1457 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 1579 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2009 | 110 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 588 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 415 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1294 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13050 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2009 | 453 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2009 | 264 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 3412 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 742 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2008 | 133 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4710 | 0.020 |
Why?
|
| Gestational Age | 1 | 2010 | 1226 | 0.010 |
Why?
|
| Placebos | 1 | 2006 | 234 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 576 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 1230 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2014 | 3731 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4684 | 0.010 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2008 | 1009 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2006 | 1254 | 0.010 |
Why?
|
| Immune Sera | 1 | 1992 | 89 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1992 | 117 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1992 | 189 | 0.010 |
Why?
|
| Biological Transport | 1 | 1992 | 348 | 0.010 |
Why?
|
| Species Specificity | 1 | 1992 | 541 | 0.010 |
Why?
|
| Rabbits | 1 | 1992 | 673 | 0.010 |
Why?
|
| Dogs | 1 | 1992 | 652 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 569 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1992 | 588 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1992 | 2669 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 3771 | 0.000 |
Why?
|